Cargando…
Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report
Adrenocortical carcinoma (ACC) is an uncommon endocrine malignancy with limited treatment options. While the overall 5-year survival rate in patients with ACC is 35%, the disease is often rapidly progressive with long-term survival in only 5% of patients. Although tumor stage, grade, and excess horm...
Autores principales: | Schreiber, Anna R, Kar, Adwitiya, Goodspeed, Andrew E, Pozdeyev, Nikita, Somerset, Hilary, Raeburn, Christopher D, Tan, Aik-Choon, Leong, Stephen, Wierman, Margaret E, Kiseljak-Vassiliades, Katja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053406/ https://www.ncbi.nlm.nih.gov/pubmed/32154490 http://dx.doi.org/10.1210/jendso/bvaa017 |
Ejemplares similares
-
Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019) -
SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019) -
OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022) -
Insights From Targeted Genetic Analysis of 364 Adrenocortical Carcinomas
por: Pozdeyev, Nikita, et al.
Publicado: (2021) -
SUN-337 Anti-tumorigenic Effects Of The Maternal Leucine Zipper Kinase (MELK) Inhibitor, OTSSP167, In Pre-clinical In Vivo Models Of Adrenocortical Carcinomas (ACC)
por: KAR, ADWITIYA, et al.
Publicado: (2019)